How is it that in the year 2024, the mass majority of medical professionals are unable to properly diagnose the clinical symptoms of botulism post Botox, Dysport, Xeomin, Jeuveau or Daxxify therapeutic or cosmetic treatments? The writing has been on the wall since 2009, when the FDA forced manufacturers to put a black box warning label onto all botulinum toxin A products stating that the product may cause severe or life-threatening side effects, disabilities, a fatality, or the development of botulism.
Botulism is diagnosed based on clinical symptoms. There are few tests that confirm it. The warning label states, that should the side effects of "loss of strength, muscle weakness, double vision, blurred vision, drooping eyelids, hoarseness, change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, or trouble swallowing occur," to contact the prescribing physician immediately. And yet, thousands upon thousands of people have experienced this, reported it to their physician, only to be turned away and told that their side effects are, "not from the product they received."
Over the last 20 years, plenty of articles and studies like this one, From Beauty to Botulism: A Case Report Highlighting the Rare Risk of Botox Administration have been in the public domain, only to be ignored by the vast majority of medical professionals. The question we are asking people today is, are medical professionals unable to diagnose botulism after Botox, or is it that they are unwilling, WHY?!
We want to thank Jordan Richardson and Shannon Viviano for providing online access to this imperative case for both medical professionals and consumers to consider, as it provides proof that botulism after using botulinum toxin A has occurred in ANOTHER individual. We appreciate greatly that this article highlights the intense need for medical professionals, emergency room physicians, and healthcare professionals worldwide to do better due diligence to familiarize themselves with the clinical symptoms of botulism post botulinum toxin A treatment. And that there is also great need to "maintain a high index of suspicion for iatrogenic botulism in patients presenting with symptoms suggestive of cranial nerve palsies and descending muscle weakness, especially when there is a history of recent Botox use."
Please follow the link above to read and share the article above.
Comments